2026-07-21T17:17:16Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/182762024-09-21T22:17:35Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16978

00925njm 22002777a 4500 dc Majem, M author Manzano, J L author Marquez-Rodas, I author Mujika, K author Muñoz-Couselo, E author Pérez-Ruiz, E author de la Cruz-Merino, L author Espinosa, E author Gonzalez-Cao, M author Berrocal, A author 2021-03-02 Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available. 10.1007/s12094-020-02539-9 1699-3055 Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico http://hdl.handle.net/10668/17259 33651321 http://hdl.handle.net/20.500.12105/18276 Adjuvant treatment metastatic treatment Melanoma Staging SEOM clinical guideline for the management of cutaneous melanoma (2020).